Search Results for: drug patents

Judd Gregg will reportedly be appointed as Sec. of Commerce today.

Here a few data points on pharmaceutical issues.

Continue Reading →

The following are KEI's January 26, 2009 remarks at the World Forum on Science and Democracy, held in Belém, Brasil, an event that is affiliated with the World Social Forum, which is also taking place in Belém the same week.

Continue Reading →

This is from an exchange on IP-Health.

———–
Dear Aidan and Thomas.

There are several things I could mention about this revised position on compulsory licenses, but I will begin with these.

Continue Reading →

This is a comment on the references to compulsory licensing in the Hollis/Pogge HIF book that are quoted below.

https://www.keionline.org/blogs/2008/11/18/excerpts-from-hif-compulsory-licensing/
Aidan Hollis and Thomas Pogge, The Health Impact Fund, Making New Medicines Accessible for All, A Report of Incentives for Global Health, 2008.

Continue Reading →

This is an exchange from the ip-health list, that will be updated as the conversation continues, about the impact of the HIF on the generic drug industry developing countries.

—– Original Message —–
From: “James Love”
To: “Ip-health”

Cc: “Thomas Pogge” “Aidan Hollis”
Sent: Wednesday, November 19, 2008 2:15 PM
Subject: impact of the HIF on generic industry in developing countries

Continue Reading →

In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about compulsory licensing of patents.

Page 53-54

Continue Reading →

In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about S.2210 (110th Congress), Senator Sanders’ proposal for the Medical Innovation Prize Fund.

Page 105-106

Medical Innovation Prize Act of 2007

Continue Reading →

Aidan Hollis and Thomas Pogge discuss Intellectual Property and the HIF.*

Intellectual Property

Continue Reading →

I have been asked to elaborate on the relationship between the Medical Innovation Prize Fund (S.2210, 110th Congress) and the WTO TRIPS Agreement.

For centuries, innovation inducement prizes have been suggested as a mechanism to stimulate investments in a wide range of topics. (See, for example, Selected Innovation Prizes and Reward Programs, KEI Research Note 2008:1). During most of this period, the patent system has also existed.

Continue Reading →